Analyst Price Targets — EYPT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 8:12 pm | Annabel Samimy | Stifel Nicolaus | $40.00 | $13.85 | TheFly | EyePoint initiated with a Buy at Stifel |
| February 19, 2026 12:17 pm | — | Mizuho Securities | $36.00 | $14.36 | TheFly | EyePoint price target raised to $36 from $33 at Mizuho |
| February 5, 2026 1:54 pm | Lisa Walter | RBC Capital | $39.00 | $13.22 | StreetInsider | RBC Capital on EyePoint Inc. (EYPT): 'We See Recent Weakness as Buying Opportunity' |
| October 29, 2025 12:50 pm | Graig Suvannavejh | Mizuho Securities | $33.00 | $12.25 | TheFly | EyePoint price target raised to $33 from $28 at Mizuho |
| October 20, 2025 10:55 am | Graig Suvannavejh | Mizuho Securities | $28.00 | $11.63 | StreetInsider | Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT) |
| November 11, 2024 12:23 pm | Yi Chen | H.C. Wainwright | $22.00 | $11.59 | StreetInsider | EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $22 at H.C. Wainwright |
| May 13, 2024 7:17 am | Yi Chen | H.C. Wainwright | $30.00 | $12.17 | StreetInsider | EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $30 at H.C. Wainwright |
| May 7, 2024 6:34 am | Graig Suvannavejh | Mizuho Securities | $30.00 | $11.20 | StreetInsider | EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $30 at Mizuho |
| August 4, 2022 6:36 am | — | H.C. Wainwright | $25.00 | $10.22 | Benzinga | HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $25 |
Latest News for EYPT
WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule…
Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives
Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near term. EyePoint Pharmaceuticals could soon be a key player in a $15 billion global market.
WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule…
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EYPT.
U.S. House Trading
No House trades found for EYPT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.